Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors

Author(s): Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli, Nicola Petrosillo

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 10 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


Sildenafil is increasingly used for the therapy of pulmonary arterial hypertension (PAH) in HIV infected patients. However, concerns exist about pharmacokinetic interactions between sildenafil and protease inhibitors (PI); in particular, ritonavir has been shown to increase sildenafil AUC and Cmax by several folds. The aim of our study was to determine the plasma levels of sildenafil and PI in two HIV patients with PAH treated with antiretroviral therapy including ritonavir-boosted PI. Our patients both experienced sildenafil Cmax above 500 ng/mL; however, they did not report any significant adverse reactions to sildenafil during the follow-up period. Therapeutic drug monitoring of sildenafil should be taken in consideration during treatment in order to avoid overdosage.

Keywords: HIV, protease inhibitors, pulmonary arterial hypertension, sildenafil

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 13 March, 2012
Page: [162 - 164]
Pages: 3
DOI: 10.2174/157016212799937263
Price: $65

Article Metrics

PDF: 19